Mobile

Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases

Mise à jour : Il y a 4 ans
Référence : NCT02582749

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Newly diagnosed metastatic prostate cancer subjects with bone metastases will be accrued to this stratified randomized 2-arm Phase II trial. Subjects will be randomized 1:2 to ADT or ADT with Radium-223 dichloride respectively.

Critère d'inclusion

  • Prostate cancer,Bone metastases,Prostate Neoplasms

Liens